Lung Cancer: How Well We Have Fared?

Authors

  • Pradeep S. Patil R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule (Maharashtra) 425405, India
  • Hitendra S. Mahajan R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule (Maharashtra) 425405, India

DOI:

https://doi.org/10.35652/IGJPS.2022.12007

Keywords:

Adenocarcinoma, Chemotherapy, EGFR, Lung cancer, Driver mutations

Abstract

Lung Cancer has been one of the most common causes of death worldwide. With the death toll increasing in millions every year globally it has become a global scourge. With poor prognosis and disappointing 5 years survival rate post diagnosis, treatment for this disease has been ambiguous. Various advances in treatment are being made but till date the 5 years survival for major patients remains a dream. This review encompasses different treatment options that are available, problems associated with treatment and future perspective for the treatment of lung cancer. © 2022 iGlobal Research and Publishing Foundation. All rights reserved.

Metrics

Metrics Loading ...

Downloads

Published

2022-01-31

How to Cite

Patil, P. S., & Mahajan, H. S. (2022). Lung Cancer: How Well We Have Fared?. Indo Global Journal of Pharmaceutical Sciences (IGJPS), 12, 82–91. https://doi.org/10.35652/IGJPS.2022.12007

Issue

Section

Articles